Which has higher valuation and earnings, VOR or LXEO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Lexeo Therapeutics N/A N/A -$99.96M -$1.15 N/A

Is VOR or LXEO more profitable?

Vor Biopharma's return on equity of 0.00% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Lexeo Therapeutics N/A -41.85% -38.03%

Does the media favor VOR or LXEO?

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Vor Biopharma. MarketBeat recorded 3 mentions for Lexeo Therapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat Lexeo Therapeutics' score of 0.60 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexeo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IMTX or LXEO?

In the previous week, Immatics had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for Immatics and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.60 beat Immatics' score of 0.25 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Lexeo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is JANX or LXEO more profitable?

Janux Therapeutics' return on equity of -11.89% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% Lexeo Therapeutics N/A -41.85% -38.03%

Does the media favor JANX or LXEO?

In the previous week, Janux Therapeutics had 3 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 6 mentions for Janux Therapeutics and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.60 beat Janux Therapeutics' score of 0.57 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexeo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer LXEO or CVAC?

Lexeo Therapeutics presently has a consensus price target of $18.13, indicating a potential upside of 561.50%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Lexeo Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer MGTX or LXEO?

In the previous week, MeiraGTx had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 5 mentions for MeiraGTx and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.60 beat MeiraGTx's score of 0.53 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lexeo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lexeo Therapeutics (LXEO) Competitors

$2.63 -0.11 (-4.01%)

Closing price 04:00 PM Eastern

Extended Trading

$2.63 0.00 (0.00%)

As of 04:14 PM Eastern

Compare

LXEO vs. VOR, IMTX, JANX, CVAC, and MGTX

Should you buy Lexeo Therapeutics stock or one of its competitors? Lexeo Therapeutics's main competitors and comparable companies include Vor Biopharma (VOR), Immatics (IMTX), Janux Therapeutics (JANX), CureVac (CVAC), and MeiraGTx (MGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lexeo Therapeutics compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Vor Biopharma has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

Vor Biopharma presently has a consensus target price of $41.71, indicating a potential upside of 118.86%. Lexeo Therapeutics has a consensus target price of $18.13, indicating a potential upside of 561.50%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Vor Biopharma. MarketBeat recorded 3 mentions for Lexeo Therapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat Lexeo Therapeutics' score of 0.60 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexeo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Vor Biopharma's return on equity of 0.00% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Lexeo Therapeutics	N/A	-41.85%	-38.03%

Summary

Vor Biopharma and Lexeo Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Immatics?

Immatics (NASDAQ:IMTX) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Lexeo Therapeutics has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	17.10	-$222.26M	-$1.86	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A

Lexeo Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Lexeo Therapeutics' return on equity of -41.85% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-495.71%	-47.41%	-39.45%
Lexeo Therapeutics	N/A	-41.85%	-38.03%

Immatics has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market.

64.4% of Immatics shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Immatics currently has a consensus price target of $19.67, indicating a potential upside of 187.95%. Lexeo Therapeutics has a consensus price target of $18.13, indicating a potential upside of 561.50%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lexeo Therapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Immatics had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for Immatics and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.60 beat Immatics' score of 0.25 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexeo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lexeo Therapeutics beats Immatics on 11 of the 14 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Janux Therapeutics has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Janux Therapeutics' return on equity of -11.89% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Lexeo Therapeutics	N/A	-41.85%	-38.03%

Lexeo Therapeutics has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	105.04	-$113.62M	-$1.64	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A

In the previous week, Janux Therapeutics had 3 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 6 mentions for Janux Therapeutics and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.60 beat Janux Therapeutics' score of 0.57 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexeo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics presently has a consensus price target of $36.46, indicating a potential upside of 112.23%. Lexeo Therapeutics has a consensus price target of $18.13, indicating a potential upside of 561.50%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Janux Therapeutics beats Lexeo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Lexeo Therapeutics compare to CureVac?

Lexeo Therapeutics (NASDAQ:LXEO) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

CureVac has a net margin of 199.92% compared to Lexeo Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-41.85%	-38.03%
CureVac	199.92%	-23.03%	-19.09%

Lexeo Therapeutics presently has a consensus price target of $18.13, indicating a potential upside of 561.50%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Lexeo Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lexeo Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

In the previous week, Lexeo Therapeutics had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Lexeo Therapeutics and 0 mentions for CureVac. Lexeo Therapeutics' average media sentiment score of 0.60 beat CureVac's score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lexeo Therapeutics	Positive
CureVac	Neutral

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CureVac has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Summary

CureVac beats Lexeo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Lexeo Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

MeiraGTx presently has a consensus target price of $24.71, suggesting a potential upside of 148.63%. Lexeo Therapeutics has a consensus target price of $18.13, suggesting a potential upside of 561.50%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MeiraGTx has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market.

Lexeo Therapeutics has lower revenue, but higher earnings than MeiraGTx. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	11.73	-$114.20M	$0.71	14.00
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A

MeiraGTx has a net margin of 19.87% compared to Lexeo Therapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Lexeo Therapeutics	N/A	-41.85%	-38.03%

In the previous week, MeiraGTx had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 5 mentions for MeiraGTx and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.60 beat MeiraGTx's score of 0.53 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexeo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MeiraGTx beats Lexeo Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Lexeo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXEO vs. The Competition

Export

Metric	Lexeo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$215.79M	$3.90B	$7.28B	$12.92B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-2.29	12.63	275.31	25.29
Price / Sales	N/A	1,151.58	556.96	76.42
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.78	16.54	10.51	5.92
Net Income	-$99.96M	-$22.69M	$3.50B	$381.04M
7 Day Performance	-20.54%	-6.63%	-4.32%	-4.38%
1 Month Performance	-37.53%	-14.38%	-8.66%	-7.26%
1 Year Performance	-69.06%	6.02%	2.01%	-4.96%

Lexeo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXEO Lexeo Therapeutics	3.5215 of 5 stars	$2.63 -4.0%	$18.13 +589.2%	-66.6%	$215.79M	N/A	N/A	59
VOR Vor Biopharma	2.4508 of 5 stars	$18.56 -0.1%	$41.71 +124.8%	-41.0%	$1.10B	N/A	N/A	76
IMTX Immatics	3.7267 of 5 stars	$7.76 +0.4%	$20.60 +165.5%	-32.3%	$1.06B	$41.70M	N/A	704	Analyst Forecast Gap Up
JANX Janux Therapeutics	2.519 of 5 stars	$17.16 +3.7%	$36.46 +112.5%	-34.7%	$1.05B	$10M	N/A	113
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXEO) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. VOR, IMTX, JANX, CVAC, and MGTX

How does Lexeo Therapeutics compare to Vor Biopharma?

Summary

How does Lexeo Therapeutics compare to Immatics?

Summary

How does Lexeo Therapeutics compare to Janux Therapeutics?

Summary

How does Lexeo Therapeutics compare to CureVac?

Summary

How does Lexeo Therapeutics compare to MeiraGTx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. VOR, IMTX, JANX, CVAC, and MGTX

How does Lexeo Therapeutics compare to Vor Biopharma?

Which has more risk & volatility, VOR or LXEO?

Do analysts recommend VOR or LXEO?

Which has higher valuation and earnings, VOR or LXEO?

Does the media favor VOR or LXEO?

Do insiders & institutionals believe in VOR or LXEO?

Is VOR or LXEO more profitable?

Summary

How does Lexeo Therapeutics compare to Immatics?

Which has preferable earnings & valuation, IMTX or LXEO?

Is IMTX or LXEO more profitable?

Which has more volatility & risk, IMTX or LXEO?

Do insiders and institutionals believe in IMTX or LXEO?

Do analysts recommend IMTX or LXEO?

Does the media favor IMTX or LXEO?

Summary

How does Lexeo Therapeutics compare to Janux Therapeutics?

Which has more risk & volatility, JANX or LXEO?

Do institutionals and insiders believe in JANX or LXEO?

Is JANX or LXEO more profitable?

Which has better earnings and valuation, JANX or LXEO?

Does the media favor JANX or LXEO?

Do analysts recommend JANX or LXEO?

Summary

How does Lexeo Therapeutics compare to CureVac?

Is LXEO or CVAC more profitable?

Do analysts prefer LXEO or CVAC?

Which has more volatility and risk, LXEO or CVAC?

Does the media refer more to LXEO or CVAC?

Do insiders & institutionals have more ownership in LXEO or CVAC?

Which has preferable valuation & earnings, LXEO or CVAC?

Summary

How does Lexeo Therapeutics compare to MeiraGTx?

Do analysts prefer MGTX or LXEO?

Do institutionals and insiders have more ownership in MGTX or LXEO?

Which has more risk & volatility, MGTX or LXEO?

Which has higher valuation and earnings, MGTX or LXEO?

Is MGTX or LXEO more profitable?

Does the media prefer MGTX or LXEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools